Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial

Post-hoc analysis Post hoc
DOI: 10.1007/s00259-025-07351-7 Publication Date: 2025-05-26T02:06:42Z